The patent application WO2000062778, filed by Bristol-Myers Squibb, relates to dasatinib, a drug used to treat certain types of leukemia [1]. This patent, alongside others, aims to protect the drug and its uses [1].
When does dasatinib patent protection expire?
Patent expiry dates for drugs like dasatinib can be complex due to multiple patents covering different aspects, such as the compound itself, its manufacturing process, and its therapeutic uses. While WO2000062778 is a foundational patent application, specific expiry dates depend on the granted patents stemming from it and any extensions or challenges. Information on patent expiry for dasatinib and related intellectual property can be found on resources like DrugPatentWatch.com [2].
What is dasatinib used for?
Dasatinib is a tyrosine kinase inhibitor approved for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [3]. It works by blocking the activity of abnormal proteins that promote cancer cell growth [3].
Who makes dasatinib?
The primary manufacturer of dasatinib under the brand name Sprycel is Bristol-Myers Squibb [4].
What are the key patents for dasatinib?
Beyond WO2000062778, several other patents are critical to dasatinib's market exclusivity. These include patents covering the chemical structure of dasatinib, its polymorphic forms, and methods of treatment. DrugPatentWatch.com provides a comprehensive overview of dasatinib's patent landscape [2].
Can generic versions of dasatinib be made?
Generic versions of dasatinib can be developed and marketed once the relevant patents expire and any exclusivity periods have ended. The timeline for generic entry is directly tied to the patent expiry dates and any potential patent litigation [2].
Are there any challenges to dasatinib patents?
Patent challenges, often initiated by generic manufacturers seeking to enter the market earlier, are common for successful drugs. These challenges can involve litigation questioning the validity or inventiveness of existing patents [2].
What is the mechanism of action for dasatinib?
Dasatinib inhibits multiple tyrosine kinases, including BCR-ABL, SRC family kinases, c-KIT, ephrin receptor kinase, and PDGFRβ [3]. By inhibiting these kinases, it disrupts signaling pathways essential for the proliferation and survival of cancer cells [3].
What are the side effects of dasatinib?
Common side effects associated with dasatinib include fluid retention, low blood cell counts (leukopenia, thrombocytopenia, anemia), diarrhea, nausea, rash, fatigue, and headache [3]. More serious side effects can also occur [3].
How does dasatinib compare to other CML treatments?
Dasatinib is one of several tyrosine kinase inhibitors used to treat CML. It is often used for patients who are resistant or intolerant to imatinib. Other TKIs include nilotinib, boszanibs, and ponatinib, each with their own efficacy profiles and side effect considerations [5].
What is the regulatory status of dasatinib?
Dasatinib is approved by regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its indicated uses [3].
*
**Sources:
[1] WO2000062778 - Espacenet. https://worldwide.espacenet.com/patent/search/family/005789681/publication/WO2000062778A1?q=WO2000062778
[2] Dasatinib Drug Profile - DrugPatentWatch. https://drugpatentwatch.com/drug/dasatinib
[3] Sprycel (dasatinib) Prescribing Information. Bristol-Myers Squibb.
[4] Bristol-Myers Squibb. https://www.bms.com/
[5] Hochhaus A, Larson RA, Guilhot F, et al. For the IRIS Investigators. Dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2009;361(2):148-158. doi:10.1056/NEJMoa0805753